Express Pharma

JUNE 12, 2024

With additional firepower, the pharma companies are looking to acquire innovative technologies specifically in precision medicine, cell and gene therapy, cancer and rare diseases, diabetes, auto-immune diseases, and weight loss which will hurl additional M&A activity. Hoffmann-LA Roche and Ors. Vs. Cipla (5). ILR(2009)Supp. (2)Delhi

Generic Medicine 105

Generic Medicine Vaccines Diabetes Immunity 105

Express Pharma

JUNE 21, 2024

With additional firepower, the pharma companies are looking to acquire innovative technologies specifically in precision medicine, cell and gene therapy, cancer and rare diseases, diabetes, auto-immune diseases, and weight loss which will hurl additional M&A activity. Hoffmann-LA Roche and Ors. Vs. Cipla5. ILR(2009)Supp.(2)Delhi

Generic Medicine 102

Generic Medicine Vaccines Diabetes Immunity 102

Express Pharma

NOVEMBER 1, 2024

The FDA’s 505(b)(2) pathway and the European Medicines Agency’s (EMA) Hybrid Pathway offer routes for drug developers to rely on previously submitted clinical data, cutting down approval times significantly. As the world’s largest manufacturer of generic medicines, India has vast potential to utilise repurposed drugs.

Drug Development 111

Drug Development Compounding Generic Medicine Vaccines 111